.png)
.png)
Total amount raised
$3.5B
Latest funding date
2025-10-29
Location
Resilience has successfully navigated 9 funding rounds, securing investments from notable entities such as Oak Hill Advisors and the Administration for Strategic Preparedness and Response. The company recently announced significant financing milestones, including a $625 million Series D round and a $410 million partnership with the Department of Defense.
Resilience's mission to broaden access to complex medicines and protect biopharmaceutical supply chains is supported by its diverse investor base, which includes venture capital firms and government agencies. Keep reading to explore the intricacies of Resilience's fundraising journey and the investors backing this innovative platform.
Resilience (National Resilience, Inc.) has raised funding across nine rounds backed by investors including Oak Hill Advisors, ARCH Venture Partners, 8VC, the U.S. Department of Defense, Mubadala, and others.
Keep reading to explore Resilience's full fundraising journey, from its launch-stage equity rounds to its most recent long-term debt financing.
What Is Resilience?
Resilience (National Resilience, Inc.) is a technology-focused, North American contract development and manufacturing organization (CDMO) dedicated to providing access to complex medicines and protecting biopharmaceutical supply chains. Headquartered in Cincinnati, Ohio (with operations in Blue Ash, OH; Philadelphia, PA; and Toronto, Canada), the company specializes in biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for small and large molecules. Founded in 2020, Resilience partners with biopharma companies to bring complex medicines to market at scale.
How Much Funding Has Resilience Raised?
- Series A
- Amount Raised: USD 50,000,000
- Date: October 2020
- Lead Investors: Magnetic Ventures
- Series B
- Amount Raised: USD 750,000,000
- Date: November 2020
- Lead Investors: ARCH Venture Partners, 8VC
- Participants: GV, NEA, Lux Capital, Foundry Group, SOSV, Venrock, Uncork Capital, Anorak Ventures, The House Fund
- Series C
- Amount Raised: USD 600,000,000
- Date: August 2021
- Lead Investors: Undisclosed
- Government Grant (Canada)
- Amount Raised: USD 164,000,000
- Date: May 2021
- Lead Investors: Government of Canada
- Series C Extension
- Amount Raised: USD 80,000,000
- Date: November 2021
- Lead Investors: Undisclosed
- Series D
- Amount Raised: USD 625,000,000
- Date: June 2022
- Lead Investors: Undisclosed (new and existing venture capital funds, public mutual funds, pension funds, biopharma companies, sovereign wealth funds, and private family offices)
- Private Equity (Mubadala)
- Amount Raised: Undisclosed
- Date: January 2023
- Lead Investors: Mubadala Investment Company
- Debt Financing (DoD)
- Amount Raised: USD 410,000,000
- Date: March 2023
- Lead Investors: U.S. Department of Defense, U.S. International Development Finance Corporation (DFC)
- Grant (ASPR)
- Amount Raised: USD 17,500,000
- Date: October 2024
- Lead Investors: Administration for Strategic Preparedness and Response (ASPR)
- Debt Financing (Oak Hill Advisors)
- Amount Raised: USD 825,000,000
- Date: October 29, 2025
- Lead Investors: Oak Hill Advisors (OHA)
Total Amount Raised: at least USD 3,521,500,000 based on disclosed funding (Mubadala equity round amount undisclosed).
Key Investors
- Oak Hill Advisors (OHA)
- Details: Oak Hill Advisors is a leading global credit-focused alternative asset manager with approximately $98 billion in AUM (as of June 2025). A private markets platform of T. Rowe Price Group, OHA led Resilience's October 2025 long-term debt financing of up to $825 million to accelerate Resilience's CDMO strategy and invest in its manufacturing operations in Cincinnati and Toronto.
- ARCH Venture Partners
- Details: ARCH Venture Partners is a leading deep-tech and life sciences venture firm. Co-founded by Robert Nelsen, ARCH was a founding co-investor and co-led Resilience's $750 million Series B in November 2020.
- 8VC
- Details: 8VC is a technology-focused venture capital firm and co-founder of Resilience. 8VC co-led the Series B alongside ARCH Venture Partners and has been a long-term backer of the company.
- Mubadala Investment Company
- Details: Mubadala is Abu Dhabi's sovereign wealth fund. In January 2023, Mubadala made an undisclosed equity investment in Resilience and agreed to fund a new biopharma manufacturing facility in the UAE, expanding Resilience's global footprint.
- U.S. Department of Defense / DFC
- Details: In March 2023, the U.S. DoD, in partnership with the International Development Finance Corporation, provided $410 million in long-term loan financing to Resilience to establish domestic end-to-end biomanufacturing capacity for biologics, vaccines, and nucleic acids.
- Administration for Strategic Preparedness and Response (ASPR)
- Details: ASPR awarded Resilience Government Services nearly $17.5 million in October 2024 to expand domestic manufacturing for critical pharmaceutical ingredients.
What's Next for Resilience?
With its latest long-term debt financing of up to $825 million from Oak Hill Advisors secured in October 2025, Resilience is focused on accelerating its CDMO strategy and expanding its advanced biomanufacturing capabilities. The company aims to invest in its manufacturing operations anchored in Cincinnati and Toronto, with the Cincinnati facility targeted to become one of the largest sterile injectable and device assembly and packaging operations in North America. Resilience continues to position itself as a critical partner for biopharma companies seeking high-quality, scalable manufacturing solutions for complex medicines, with a long-term vision of strengthening domestic and global biopharmaceutical supply chain resilience.
Use Clay to Get Funding Data
Sales professionals, leverage Clay's platform to access comprehensive fundraising data. Sign up for free today.
